Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone-results from a post-marketing surveillance trial under daily routine conditions

Diabetes Technology and Therapeutics

Volumn 11, Issue 6, 2009, Pages 379-383

  Schöndorf, Thomas ^a,b,d   Karagiannis, Efstrathios ^c   Posseldt, Richard E K ^a   Forst, Thomas ^a   Pfützner, Andreas ^a  

^a IKFE Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Takeda Pharma GmbH   (Germany)

^d IKFE GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; COMPETACT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS PIOGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACKACHE; BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; EDEMA; ERECTILE DYSFUNCTION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 67649841976     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0108     Document Type: Article

References (17)

1. Kahn CR: Banting Lecture: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994;43:1066-1084.
2. Hamman RF: Genetic and environmental determinants of non-insulin- dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992;8:287-338.
3. Stafford JM, Elasy T: Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vasc Health Risk Manag 2007;3:503-510.
4. Molavi B, Rassouli N, Bagwe S, Rasouli N: A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag 2007;3:967-973.
5. Cusi K, Consoli A, DeFronzo RA: Metabolic effects of met-formin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-4067.
6. Dorella M, Giusto M, Da Tos V, Campagnolo M, Palatini P, Rossi G, Ceolotto G, Felice M, Semplicini A, Del Prato S: Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996;81:1568-1574.
7. Gunton JE, Delhanty PJ, Takhashi S, Baxter RC: Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 2003;88:1323-1332.
8. Pfützner A, Forst T: Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. Expert Opin Pharmacother 2006;7:463-476.
9. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-1702.
10. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; Quartet Study Group: A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405.
11. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combintion with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitzone 027 Study Group. Clin Ther 2000;22:1395-1409.
12. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G: Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-174.
13. Seufert J, Urquart R: 2-year effect of pioglitazone add-on sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79:453-460.
14. Johnson JA, Simpson SH, Toth EL, Majumdar SR: Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005;22:497-502.
15. Natali A, Ferrannini E: Effects of metformin and thiazolidi-nediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-441.
16. Chalmers J, Hunter JE, Robertson SJ, Baird J, Martin M, Franks CI, Whately-Smith CR, Mariz S, Campbell IW: Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes. Cur Med Res Opin 2007;23:1775-1781.
17. Hill NR, Matthews DR: Pioglitazone and metformin. Drugs Today 2007;43:443-454.